INFILTRATIVE PULMONARY TUBERCULOSIS: IMMUNOPATHOGENETIC MECHANISMS OF DEVELOPMENT AND DISORDER OF METABOLISM OF XENOBIOTICS

DOI: https://doi.org/None

Gurova Ya.V., Mordyk A.V.

In the context of the continuing importance of the problem of tuberculosis there must be the selection both of priority areas to combat it, and priority category of patients. The most common form of TB among new cases is infiltrative and successful treatment of this form determines the effectiveness of the treatment of the entire cohort of patients. In this regard, the survey was attempted as to highlight immunopathogenetic mechanisms of infiltrative tuberculosis and metabolic features of anti-TB drugs as to detect areas of research to reveal primary factors that determine the success or the failure of the treatment of these patients. The use of results of immunological investigations of genotyping will allow to predict the failure in the treatment of newly diagnosed patients with infiltrative tuberculosis and promptly remove impediments to the favorable outcome of chemotherapy.
Keywords: 
infiltrative pulmonary tuberculosis, immunological reactivity, pathogenesis, anti-TB drugs, the metabolism
Список литературы: 
  1. Bazhora Yu.I., Kresyun V.I., Fecenko Yu.I., Asmolov A.K., Nikolaevskiy V.V. Molekulyarno-geneticheskie mehanizmy tuberkuleznoy infekcii. Odessa: Odesskiy gosudarstvennyy medicinskiy universitet, 2005; 296. [Bazhora Ju.I., Kresjun V.I., Fecenko Ju.I., Asmolov A.K., Nikolaevskij V.V. Molekuljarno-geneticheskie mehanizmy tuberkuleznoj infekcii. Odessa: Odesskij gosudarstvennyj medicinskij universitet, 2005; 296 (in Russian)]
  2. Mordyk A.V., Puzyreva L.V., Aksyutina L.P. Sovremennye mezhdunarodnye i nacional`nye koncepcii bor`by s tuberkulezom. Dal`nevostochnyy zhurnal infekcionnoy patologii. 2013; 22: 92–7. [Mordyk A.V., Puzyreva L.V., Aksjutina L.P. Sovremennye mezhdunarodnye i nacional’nye koncepcii bor’by s tuberkulezom. Dal’nevostochnyj zhurnal infekcionnoj patologii. 2013; 22: 92–7 (in Russian)]
  3. Gergert V.Ya. Immunologiya tuberkuleza. Tuberkulez segodnya: problemy i perspektivy. M., 2000; 18–21. [Gergert V.Ja. Immunologija tuberkuleza. Tuberkulez segodnja: problemy i perspektivy. M., 2000; 18–21 (in Russian)]
  4. Ivanova O.G., Mordyk A.V., Puzyreva L.V E`ffektivnost` meropriyatiy po vyyavleniyu tuberkuleza organov dyhaniya v Omskoy oblasti. Kubanskiy nauchnyy medicinskiy vestnik. 2011; 4: 102–4. [Ivanova O.G., Mordyk A.V., Puzyreva L.V. Jeffektivnost’ mero-prijatij po vyjavleniju tuberkuleza organov dyhanija v Omskoj oblasti. Kubanskij nauchnyj medicinskij vestnik. 2011; 4: 102–4 (in Russian)]
  5. Koreckaya N.M., Narkevich A.A., Narkevich A.N. Gendernye osobennosti vpervye vyyavlennogo infil`trativnogo tuberkuleza legkih. Pul`monologiya. 2014; 1: 77–80.[Koreckaja N.M., Narkevich A.A., Narkevich A.N. Gendernye osobennosti vpervye vyjavlennogo infil’trativnogo tuberkuleza legkih. Pul’monologija. 2014; 1: 77–80 (in Russian)]
  6. Lysov A.V., Ivanova O.G., Mordyk A.V., Antropova V.V. Infil`trativnyy tuberkulez legkih u lic starshe 60 let. Tuberkulez i bolezni legkih. 2008; 1: 28–30. [Lysov A.V., Ivanova O.G., Mordyk A.V., Antropova V.V. Infil’trativnyj tuberkulez legkih u lic starshe 60 let. Tuberkulez i bolezni legkih. 2008; 1: 28–30 (in Russian)]
  7. Novickiy V.V., Strelis A.K., Urazova O.I., Voronkova O.V., Tkachenko S.B., Sinicyna V.A., Filinyuk O.V., Zemlenaya N.A., Shil`ko T.A., Esimova I.E., Perevozchikova T.V. Osobennosti funkcional`noy aktivnosti limfocitov krovi u bol`nyh tuberkulezom legkih. Immunologiya. 2006; 2: 76–9. [Novickij V.V., Strelis A.K., Urazova O.I., Voronkova O.V., Tkachenko S.B., Sinicyna V.A., Filinjuk O.V., Zemlenaja N.A., Shil’ko T.A., Esimova I.E., Perevozchikova T.V. Osobennosti funkcional’noj aktivnosti limfocitov krovi u bol’nyh tuberkulezom legkih. Immunologija. 2006; 2: 76–9 (in Russian)]
  8. Mordyk A.V., Ivanova O.G. Kliniko-rentgenologicheskie harakteristiki i e`ffektivnost` lecheniya bol`nyh infil`trativnym tuberkulezom legkih s razlichnymi izmeneniyami vegetativnogo gomeostaza. Tuberkulez i bolezni legkih. 2010; 5: 31–7. [Mordyk A.V., Ivanova O.G. Kliniko-rentgenologicheskie harakteristiki i jeffektivnost’ lechenija bol’nyh infil’trativnym tuberkulezom legkih s razlichnymi izmenenijami vegetativnogo gomeostaza. Tuberkulez i bolezni legkih. 2010; 5: 31–7 (in Russian)]
  9. Sennikov S.V., Silkov A.N. Metody opredeleniya citokinov. Citokiny i vospalenie. 2005; 1: 22–7. [Sennikov S.V., Silkov A.N. Metody opredelenija citokinov. Citokiny i vospalenie. 2005; 1: 22–7 (in Russian)]
  10. Mordyk A.V., Cygankova E.A., Puzyreva L.V., Turica A.A. Protivotuberkuleznyy immunitet i mehanizmy ego formirovaniya (obzor literatury). Dal`nevostochnyy medicinskiy zhurnal. 2014; 1: 126–30. [Mordyk A.V., Cygankova E.A., Puzyreva L.V., Turica A.A. Protivotuberkuleznyj immunitet i mehanizmy ego formirovanija (obzor literatury). Dal’nevostochnyj medicinskij zhurnal. 2014; 1: 126–30 (in Russian)]
  11. Dheda K., Zyl-Smit R.N. van, Meldau R., Meldau S., Symons G., Khalfey H., Govender N., Rosu V., Sechi L.A., Maredza A., Semple P., Whitelaw A., Wainwright H., Badri M., Dawson R., Bateman E.D., Zumla A. Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis. Thorax. 2009; 64: 847–53.
  12. Suleymanov S.Sh., Shepeleva E.N., Volkov A.V., Guvva T.L., Markova S.M. Analiz osobennostey fenotipa acetilirovaniya u bol`nyh arterial`noy gipertenziey. Zdravoohranenie Dal`nego Vostoka. 2003; 2: 11–4. [Sulejmanov S.Sh., Shepeleva E.N., Volkov A.V., Guvva T.L., Markova S.M. Analiz osobennostej fenotipa acetilirovanija u bol’nyh arterial’noj gipertenziej. Zdravoohranenie Dal’nego Vostoka. 2003; 2: 11–4 (in Russian)]
  13. Ftiziatriya: nacional`noe rukovodstvo. Pod red. M.I. Perel`mana. M.: GE`OTAR-Media, 2007; 512. [Ftiziatrija: nacional’noe rukovodstvo. Pod red. M.I. Perel’mana. M.: GJeOTAR-Media, 2007; 512 (in Russian)]
  14. Safronov A.E., Markelova E.V. Vozmozhnosti ispol`zovaniya pokazateley IL-6 i ego receptora v kachestve dopolnitel`nogo kriteriya rasprostranennosti tuberkuleza organov dyhaniya u detey i podrostkov. Medicinskaya immunologiya. 2009; 4–5: 396. [Safronov A.E., Markelova E.V. Vozmozhnosti ispol’zovanija pokazatelej IL-6 i ego receptora v kachestve dopolnitel’nogo kriterija rasprostranennosti tuberkuleza organov dyhanija u detej i podrostkov. Medicinskaja immunologija. 2009; 4–5: 396 (in Russian)]
  15. Almeida A.S., Lago P.M., Boechat N., Huard R.C., Lazzarini L.C.O., Santos A.R., Nociari M., Zhu H., Perez-Sweeney B.M., Bang H., Ni Q., Huang J., Gibson A.L., Flores V.C., Pecanha L.R., Kritski A.L., Lapa e Silva J.R., Ho J.L. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J. Immunol. 2009; 183: 718–31.
  16. Bothamley G.H. New tests for tuberculosis: local immune responses have greater specificity. Thorax. 2008; 1: 4–5.
  17. Djoba Siawaya J.F., Bapela N.B., Ronacher K., Beyers N., Helden P. van, Walzl G. Differential Expression of Interleukin-4 (IL-4) and IL-4{delta}2 mRNA, but Not Transforming Growth Factor Beta (TGF-{beta}), TGF-{beta}RII, Foxp3, Gamma Interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment. Clin. Vaccine Immunol. 2008; 8: 1165–70.
  18. Evans W.E., McLeod H.L. N. Engl. J. Med. 2003; 6: 538–49.
  19. Moskalev A., Plyusnina E., Shaposhnikov M., Shilova L., Kazachenok A., Zhavoronkov A. The role of D-GADD45 in oxidative, thermal and genotoxic stress resistance. Cell. Cycle. 2012; 11 (22): 4222–41.
  20. Bochkov N.P. Geneticheskie podhody k ocenke bezopasnosti i e`ffektivnosti lekarstvennyh sredstv. Klinicheskie issledovaniya lekarstvennyh sredstv v Rossii. 2002. 2: 4–6. [Bochkov N.P. Geneticheskie podhody k ocenke bezopasnosti i jeffektivnosti lekarstvennyh sredstv. Klinicheskie issledovanija lekarstvennyh sredstv v Rossii. 2002. 2: 4–6 (in Russian)]
  21. Druzhinina Yu.G., Ryzhikova S.L., Ryabicheva T.G., Varaksin N.A. Opredelenie urovney spontannoy i mitogen inducirovannoy produkcii citokinov uslovno zdorovyh donorov ex vivo. Medicinskaya immunologiya. 2009; 4–5: 473. [Druzhinina Ju.G., Ryzhikova S.L., Rjabicheva T.G., Varaksin N.A. Opredelenie urovnej spontannoj i mitogen inducirovannoj produkcii citokinov uslovno zdorovyh donorov ex vivo. Medicinskaja immunologija. 2009; 4–5: 473 (in Russian)]
  22. Ershov F.I., Kiselev O.I. Interferony i ih induktory (ot molekuly do lekarstva). M.: GE`OTAR-Media, 2005; 368. [Ershov F.I., Kiselev O.I. Interferony i ih induktory (ot molekuly do lekarstva). M.: GJeOTAR-Media, 2005; 368 (in Russian)]
  23. Mordovskaya L.I., Vladimirskiy M.A., Aksenova V.A. Indukciya interferona v obrazcah cel`noy krovi in vitro – test dlya opredeleniya tuberkuleznogo inficirovaniya detey i podrostkov. Problemy tuberkuleza. 2009; 7: 19–24. [Mordovskaja L.I., Vladimirskij M.A., Aksenova V.A. Indukcija interferona v obrazcah cel’noj krovi in vitro – test dlja opredelenija tuberkuleznogo inficirovanija detej i podrostkov. Problemy tuberkuleza. 2009; 7: 19–24 (in Russian)]
  24. Zheleznikova G.F. Citokiny kak prediktory techeniya i ishoda infekciy. Citokiny i vospalenie. 2009; 1: 10–8. [Zheleznikova G.F. Citokiny kak prediktory techenija i ishoda infekcij. Citokiny i vospalenie. 2009; 1: 10–8 (in Russian)]
  25. Royt A., Brostoff Dzh., Meyl D. Immunologiya. M.: Mir, 2000; 582. [Rojt A., Brostoff Dzh., Mejl D. Immunologija. M.: Mir, 2000; 582 (in Russian)]
  26. Lella R.K., Sharma C. EIS (enhanced intracellular survival) protein of Mycobacterium tuberculosis disturbs the cross regulation of T-cells. J. Biol. Chem. 2007; 282 (26): 18671–5.
  27. Ignat`ev I.V., Sychev D.A., Andreev D.A. Medicinskaya genetika. 2005; 12: 568–72. Ignat’ev I.V., Sychev D.A., Andreev D.A. Medicinskaja genetika. 2005; 12: 568–72 (in Russian)]
  28. Kukes V.G. Metabolizm lekarstvennyh sredstv: kliniko-farmakologicheskie aspekty. M.: Reafarm, 2004; 144. [Kukes V.G. Metabolizm lekarstvennyh sredstv: kliniko-farmakologicheskie aspekty. M.: Reafarm, 2004; 144 (in Russian)]
  29. Lakin K.M., Krylov Yu.F. Biotransformaciya lekarstvennyh veshhestv. M.: Medicina, 1981; 344. [Lakin K.M., Krylov Ju.F. Biotransformacija lekarstvennyh ve-shhestv. M.: Medicina, 1981; 344 (in Russian)]
  30. Chou W.H., Yan F.X., de Leon J., Barnhill J., Rogers T., Cronin M. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. Psychopharmacol. 2000; 20: 246–51.
  31. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. 2003; 59 (4): 303–12.
  32. Kirchheiner J., Fuhr U., Brockmoller J. Nat. Rev. Drug. Discov. 2005; 4 (8): 639–47.
  33. Lil`in E.T. Vvedenie v sovremennuyu farmakogenetiku. M.: Medicina, 1984; 160. [Lil’in E.T. Vvedenie v sovremennuju farmakogenetiku. M.: Medicina, 1984; 160 (in Russian)]
  34. Moskalev A.A., Plyusnina E.N., Shaposhnikov M.V. Radiation hormesis and radioadaptive response in Drosophila melanogaster flies with different genetic backgrounds: the role of cellular stress-resistance mechnisms. Biogerontology. Springer, 2011; 12 (3): 253–63.
  35. Moskalev A.A. E`volyucionnye predstavleniya o prirode stareniya. Uspehi gerontologii. 2010; 1: 9–20. [Moskalev A.A. Jevoljucionnye predstavlenija o prirode starenija. Uspehi gerontologii. 2010; 1: 9–20 (in Russian)]
  36. Fruech F.W. Education in pharmacogenomics: closing the gap between possibility and realility. http: //www.fda.gov/cder/genomics/ presentations.htm [e`lektronnyy resurs] – Data obrashheniya 08.04.2015 g..
  37. Seredenin S.B. Lekcii po farmakogenetike. M.: MIA, 2004; 336. [Seredenin S.B. Lekcii po farmakogenetike. M.: MIA, 2004; 336 (in Russian)]
  38. Gardiner S.J., Begg E.J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacogenet. Genomics. 2005; 15 (5): 365–9.
  39. Moskalev A.A., Shaposhnikov M.V. Pharmacological inhibition of phosphoinositide 3 and TOR kinases improves survival of Drosophila melanogaster. Rejuvenation Research. 2010; 13 (2–3): 246–7.
  40. Moskalev A.A., Smit-McBride Z., Shaposhnikov M.V., Plyusnina E.N., Zhavoronkov A., Budovsky A., Tacutu R., Fraifeld V.E. Gadd45 proteins: relevance to aging, longevity and age-related pathologies. Ageing Research Reviews. 2012; 11 (1): 51–66.
  41. Moskalev A., Shaposhnikov M., Turysheva E. Life span alteration after irradiation in Drosophila melanogaster strains with mutations of HSF and SPS. Biogerontology. Springer, 2009; 10 (1): 3–11.
  42. Thorn C.F., Klein T.E., Altman R.B. Pharm GKB: The Pharmacogenetics and Pharmacogenomics Knowledge Base. Methods Mol. Biol. 2005; 311: 179–92.
  43. You J.H., Chan F. W., Wong R.S., Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy – a decision analysis. Thromb. Haemost. 2004; 3: 590–7.
  44. Plyusnina E.N., Shaposhnikov M.V., Moskalev A.A. Increase of Drosophila melanogaster lifespan due to D-GADD45 overexpression in the nervous system. Biogerontology. Springer, 2011; 12 (3): 211–26.
  45. Wedlund P.J., Aslanian W.S., McAllister C.B., Wilkinson G.R., Branch R.A. The CYP2C19 enzyme polymorphism. Pharmacology. 2000; 61 (3): 174–83.
  46. Moskalev A.A., Shaposhnikov M.V. Pharmacological inhibition of NF-κB prolongs lifespan of Drosophila melanogaster. Aging (Albany NY). 2011; 3 (4): 391–4.
  47. Xie H.G., Prasad H.C., Kim R.B., Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug. Deliv. Rev. 2002; 54: 1257–70.
  48. Silber B.M., Kalow W., Meyer U., Tyndale R.F. Pharmacogenomics. New York: Marcel Dekker, 2001; 323.
  49. Pharmacogenomics / ed. by Rothstein M.A. New Jersey: Willy-liss, 2003; 383.